38 results about "Hcv vaccine" patented technology

Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1 a/1 b NS3 and NS4A. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.

Disclosed are methods and compositions for inducing immune responses against Hepatitis C virus (HCV). The compositions comprise one or more epitope from a hotspot epitope. In certain embodiments, an HCV vaccine comprising at least two epitopes, each from a different hotspot epitope, is provided.

Disclosed are methods and compositions for inducing immune responses against Hepatitis C virus (HCV). The compositions comprise one or more epitope from a hotspot epitope. In certain embodiments, an HCV vaccine comprising at least two epitopes, each from a different hotspot epitope, is provided.

The invention discloses a DNA (deoxyribonucleic acid) segment and applications thereof in constructing an HCV (hepatitis C virus) whole-genome expression animal model. The nucleotide sequence of the DNA segment comprises the following sequentially series connected sequences: an operator gene sequence of bacteria tetracycline drug-resistance operon, an immediate early promoter gene sequence of human macrophage, a gene sequence of HCV whole genome, and a gene sequence of ribozyme shearing the HCV whole genome activity on DNA and/or RNA (ribonucleic acid) level. The DNA segment can be used for constructing a tetracycline or tetracycline derivative-induced HCV whole genome-expressed transgenic animal model. The immunity of the animal model is normal, thereby being capable of producing specific anti-virus immunoreaction aiming at the expression of the HCV, and further being effectively applied to the research on the immunopathogenesis damage mechanism of drug evaluation and virus infection of the HCV vaccine.

The invention relates to the technical field of biological engineering. At present, there is no effective vaccine for preventing hepatitis C virus (HCV) infection. The amino terminal of HCV envelope protein E2 has 27 amino acid residues with highest variability, known as hypervariable region 1(HVR1). The invention provides an HCV envelope protein E2 without HVR1, also provides an application of the HCV envelope protein E2 without HVR1 on HCV vaccines and HCV infection immunity diagnostic reagents. Animal immunization tests have discovered that HVR1 in 1-6 genotype HCV envelope protein E2 has substantial inhibition effect against immunogenicity of conservative neutralizing epitope in the envelope protein E2, the effectiveness of inducting broad spectrum neutralizing antibody by the E2 protein is significantly enhanced by deleting HVR1, the HCV envelope protein E2 with deleting HVR1 possibly can be used as an effective target antigen of HCV vaccines. The invention has proved that the HCV envelope protein E2 with deleting HVR1 has strong reaction with E2 antibody in serums of HCV infections and can be used as an immunity diagnostic antigen of HCV infections.

Identification of HCV receptor target cells using HCV receptor-binding ligands and cell separation by flow cytofluorimetry is described. HCV receptor target cells are employed to conduct assays for HCV receptor-binding ligands in order to identify potential HCV vaccine candidates. HCV receptor target cells are used to measure antibody neutralisation to monitor vaccine development, as a diagnostic of HCV infection and to develop neutralising antibodies for passive immunisation.

An anti-HCV vaccine, which is prepared through recombination of an NS gene in series, including NS3/NS4 and NS4/NS5, with an adenovirus vector. The preparation methods and uses of the anti-HCV vaccine.

Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and NS5B. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.

The invention relates to a method for preventing or treating Hepatitis C Virus (HCVi) infections, wherein a HCV vaccine comprising an effective amount of at least one HCV T-cell antigen and a polycationic compound comprising peptide bonds is administered to a human individual bi-weekly at least 3 times.

The present disclosure provides immunogenic compositions comprising HCV E1, E2, or E1/E2 polypeptides from two or more different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1/E2 polypeptides from two or more different HCV genotypes. The immunogenic compositions are useful in carrying out methods of inducing an immune response to HCV. The present disclosure further provides methods of stimulating an immune response to HCV in an individual.